Main author: Maribel Quintana Esquivel
Summary: In 1987, it was established for the first time in our country a production process through which Interferon Alpha-2b Hu-r was obtained, from bacteria genetically manipulated. This process was increased until there was obtained a volume enough to cover national and export needs. This technological productive improvement allowed obtaining a high-quality and pure product, able to compete worldwide with interferons produced by foreign companies. The production of a gram of Interferon Alpha-2b Hu-r saves approximately 1 million of MLC to the country that would have cost the import of such a quantity of product, and up to 50 times more can be produced for the same value. From the social point of view, it guarantees the possibility to apply new clinical treatments for diseases such as different types of cancer, hepatitis, herpes, viruses and others. Different pharmaceutical forms of this medication are available: collyrium, cream, nasal spray, etc. PERFORMERS: Center of Genetic Engineering and Biotechnology